|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2009-3-30
|
|
pubmed:abstractText |
Serum paraoxonase (PON1) exerts antiatherogenic effects. Novel PON1 enzymatic tests have been recently developed: 5-thiobutyl butyrolactone (TBBL) estimates PON1 lactonase activity, whereas 7-O-diethylphosphoryl-3-cyano-4-methyl-7-hydroxycoumarin (DEPCyMC) is considered a surrogate marker of PON1 concentration. The TBBL to DEPCyMC ratio provides the normalized lactonase activity (NLA), which may reflect the degree of PON1 lactonase catalytic stimulation. The aim of this study was to evaluate for the first time TBBLase and DEPCyMCase activity in patients with coronary artery disease (CAD).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1434-6621
|
|
pubmed:author |
pubmed-author:AnnarummaLauraL,
pubmed-author:BassiAntonellaA,
pubmed-author:BozziniClaudiaC,
pubmed-author:CorrocherRobertoR,
pubmed-author:Franco PignattiPierP,
pubmed-author:FrisoSimonettaS,
pubmed-author:GirelliDomenicoD,
pubmed-author:GuariniPatriziaP,
pubmed-author:MartinelliNicolaN,
pubmed-author:PalR SRS,
pubmed-author:PizzoloFrancescaF,
pubmed-author:SchiavonRenzoR,
pubmed-author:TenutiIlariaI,
pubmed-author:TrabettiElisabettaE
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
432-40
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Novel serum paraoxonase activity assays are associated with coronary artery disease.
|
|
pubmed:affiliation |
Department of Clinical and Experimental Medicine, University of Verona, Verona, Italy. nicola.martinelli@univr.it
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
